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Introduction
Pulmonary vein isolation (PVI) is a well-established treatment for symptomatic paroxysmal atrial fibrillation (AF) and can be considered as a first-line therapy in patients with structurally normal heart. 1 However, the generally used "point by point" ablation technique to isolate pulmonary veins (PVs) is still time consuming and requires experienced operators to perform and create reliable contiguous transmural lesions. In order to overcome these limitations, a simultaneous multipolar nonirrigated radiofrequency (RF) ablation catheter has been introduced in clinical practice. 2 Unfortunately the use of this catheter has been correlated with a high incidence of silent cerebral ischemia (SCI). 3, 4 Recently a new catheter (nMARQ TM Circular, Biosense Webster Inc, Diamond Bar, California) combining both 3D electroanatomic mapping (EAM) and multipolar RF ablation capability through open-irrigation design has recently been developed. Preliminary reports on PVI with nMARQ TM showed a good acute success but still with a high incidence of complications such as SCI and atrio-esophageal fistulas. 5, 6, 7 Moreover, most of these preliminary studies did not provide confirmation of PVI with the standard circular multipolar mapping method and did not strictly apply the methodology proposed at the present time to reduce the incidence of SCI using the RF multielectrode ablation catheter. 8 The present study aimed to assess, in patients with paroxysmal AF undergoing PVI with the use of this new catheter, the followings: 1) feasibility; 2) acute success validated with the Lasso catheter (BiosenseWebster, Diamond Bar, USA); 3) safety with particular interest on the incidence of periprocedural SCI by performing cerebral diffusion-weighted magnetic resonance imaging (DW-MRI) before and after the procedure; 4) short term follow-up (6 months).
Methods

Study Population and Protocol
Twenty-five consecutive patients with drug-refractory paroxysmal AF undergoing PVI were prospectively enrolled. Exclusion criteria were: age <20 and >80 years, severe valvular heart disease, acute coronary syndrome in the last 3 months, previous AF catheter ablation, previous pacemaker or implantable cardioverter-defibrillator implant, any contraindication to cerebral MRI. All patients gave written informed consent before enrollment.
On admission all patients underwent a thorough cardiac assessment including transesophageal echocardiogram. All the patients underwent cerebral MRI 24 hours before and 24 hours after the ablation. The antithrombotic therapy was discontinued 5 days before admission and replaced by low molecular weight heparin (LMWH) dosed according to the body weight (1 mg/kg BD), until 12 hours before the procedure.
Cerebral MRI Imaging
Cerebral MRI was performed, using a 1.5 T scanner (1.5 Tesla Magnetom Avanto, Siemens, Erlangen, Germany). The detailed cerebral MRI imaging protocol has been previously reported 9 .
Briefly, the imaging protocol included a sagittal T1-weighted spin echo sequence; an axial fluidattenuated inversion recovery (FLAIR) sequence; a diffusion-weighted (DW) sequence. In the postablation MRI, acute embolic lesion was defined as a new focal hyperintense area detected by the FLAIR sequence, corresponding to a restricted diffusion signal in the DW sequence and confirmed by the apparent diffusion coefficient mapping to rule out a shine through artifact. The size and the location of the focal lesions were analyzed. Two blinded certified radiologists independently analyzed all MRI images. Interobserver variability for the MRI assessment was tested with the McNemar test and was not statistically significant. Through femoral vein access, a decapolar electrode catheter was inserted into the coronary sinus.
The LA was accessed by a single transseptal puncture using an 8.5 F long sheath continuously perfused with heparinized solution. Intravenous unfractionated heparin (100 IU/kg) was administered as follows: a third of the dose after femoral access and two-thirds of dose immediately after the transseptal puncture. The activated clotting time (ACT) was determined every 30 min and additional boluses were administered aiming to maintain ACT >320 seconds throughout the procedure. Catheters were introduced in the LA through the long sheath that was systematically withdrawn back to the right atrium after the positioning of the catheters in the LA. Frontiers, Inc., Carlsbad, CA, USA) 8, 10, 11 and with the use of nMARQ TM 5, 7 showed that specific procedural settings correlated with the incidence of embolic complications. Based on these considerations the following work-flow aiming to reduce periprocedural complications was instituted:
1. the procedures were performed on intravenous unfractionated heparin (UFH) to keep ACT >320 seconds, monitored every 30 min. UFH (100 UI/Kg) was administered as follows: 1/3 after the femoral access and the remaining 2/3 immediately after the transseptal puncture.
2. Catheters introduction and withdrawal were performed always aspirating from the sheath during their manipulation.
3. Transseptal sheath was continuously perfused with heparinized solution and it was systematically withdrawn back to the right atrium after LA catheters positioning.
4. RF energy was delivered only in unipolar mode.
5. In case of distal and proximal nMARQ TM electrodes overlapping, RF energy was delivered only through one of them, in order to avoid any energy cross-talk that may favor over-heating and thrombus formation 10,11 .
6. The maximum duration of each multielectrode application session was set to no more than 40 sec.
7. The target temperature was set to 45°C.
8. The power delivered was set to 20W and decreased to 18W in the posterior wall in order to reduce the risk of esophageal injury, 9. The electrodes showing the absence of heating over 36°C or reaching less than 10 Watt were turned off.
10. Pacing at high output (10 mA) was performed from each nMARQ TM electrodes at the right-sided veins ostium, before RF delivery, in order to avoid the phrenic nerve palsy.
Therefore the electrodes showing diaphragm capture, were switched off during RF delivery.
Follow up
Follow-up visits were scheduled at 3 and 6 months with physical examination, ECG, and 24-hour 
Results
Out of 25 patients with paroxysmal AF enrolled, 19 (76%) were male with a mean age of 57±13 years. Three (12%) patients showed ischemic heart disease while systemic hypertension was present in 13 (52%). The mean LA antero-posterior diameter was 44±8 mm while the mean left ventricular ejection fraction (LVEF) was 61±6%. A patent foramen ovale was found in 2 patients (8%). CHA 2 DS 2 -VASc score was 0 in 7 (28%), 1 in 9 (36%), ≥ 2 in 9 (36%) patients. The 
Feasibility and procedural details
The ablation procedure was feasible in all the patients (Fig.1) . The nMARQ TM catheter was easily manoeuvred without requiring the use of a steerable sheath in all the patients.
Procedural details, including fluoroscopic and procedural times at different ablation steps, are summarized in table 2 while table 3 shows, for each vein, overall RF time, mean power and mean number of active electrodes. Nineteen out of 25 enrolled patients showed 4 PVs, 2 a left common trunk, and 4 patients had a right middle PV. In these latter patients, the anatomical encircling around the right superior and/or inferior PVs allowed to electrically isolate the right middle PV using the nMARQ TM only (Fig.2) . Overall, the mean RF time was 14.95 min while the mean power was 18.07 W and the mean number of activated electrodes was 6.62 for each vein. No significant difference among veins in term of procedural parameters considered was observed except for a longer RF time needed to achieve PVI in left superior PV (LSPV) and right superior PV (RSPV) when compared to left inferior PV (LIPV) (p=0.019) and right inferior PV (RIPV) (p=0.011), respectively.
Acute success
After a first round of several multielectrodes RF deliveries with the nMARQ TM at each PV ostia obtaining the supposed PVI, Lasso catheter mapping confirmed the PVI in 80 (78%) out of 102
PVs. In the remaining 22 (22%), Lasso mapping still demonstrated venoatrial connection and further nMARQ TM RF applications were required at the LSPV in 5, LIPV in 4, RIPV in 6, and RSPV in 7 patients to obtain PVI).
At the end of the ablation procedure, PVI obtained with the use of the nMARQ TM only and confirmed with the Lasso mapping, was achieved in 100 out of 102 (98%) identified and targeted PVs and in 24 out of 25 (96%) treated patients. In the remaining patient, despite two rounds of multielectrodes RF delivery attempts with nMARQ TM catheter, a residual conduction gap still remained in the area of the ridge between LSPV and left atrial appendage (LAA). PVI was safely and effectively achieved using a 3.5-mm tip open-irrigated catheter. Moreover, in the same patient, phrenic nerve capture was observed in a quite large area around the anterior and inferior aspect of RSPV ostium and antrum (Fig. 3) . PVI of this RSPV was obtained with an anatomytailored point-by-point ablation strategy using the 3.5-mm tip open-irrigated catheter.
Safety outcome
Out of 25 procedures performed no major complications were observed. Post-procedural cerebral DW-MRI did not show any new SCI in all the patients. Only 3 groin hematomas occurred.
Six-months follow up
All patients completed the six-month follow up. No late adverse events (including cerebral thromboembolic events) were reported. Out of 25 patients 17 (68%) were in sinus rhythm and free from symptomatic or documented asymptomatic atrial arrhythmias, without AADs. Of the remaining 8 patients, 3 had documented AF episodes, 2 had symptomatic episodes without ECG/ECG Holter documentation and 3 had atypical atrial flutter.
Discussion
The major findings of the present study are the followings:
-PVI with the nMARQ TM catheter seems feasible with procedural and fluoroscopy times similar or even inferior to those reported with other existing ablation systems. This finding may influence the outcome of the procedure if performed without the Lasso catheter validation.
-Our preliminary data showed that nMARQ TM catheter appears to be safe with no major procedural complications. In particular, applying a specific procedural work-flow, no new SCI were detected by post-ablation brain MRI.
"Point-by-point" ablation for PVI using conventional irrigated catheters is now widely used. alternative for PVI with a high acute success rate. 5, 6 Our experience showed similar results in terms of procedural times and acute success rate.
Comparing the procedural time between the "point by point" ablation technique and the nMARQ TM ablation in our experience, no reduction was seen. It can be explained by our study protocol that imply extra procedural time due to the use of Lasso catheter mapping to validate the supposed PVI by the nMARQ TM . Thus, considering the learning curve and the avoidance of the use of the Lasso catheter mapping in standard procedures, a further reduction of the procedural time may be expected. In addition, the manoeuvrability of the catheter was satisfactory since PVI was obtained in all the cases without the use of steerable sheath in contrast to other experiences 5, 6, 13 . It is well known that PVs anatomy variability is remarkable 14 and, because of that, the use of circular multipolar ablation catheter may present some limitations. Nevertheless, in our study, the nMARQ TM catheter allowed us to achieve PVI in all the patients but 1 (96%). In this patient, LSPV was not isolated due to the impossibility to achieve a transmural lesion at the ridge between the left PVs and the LAA with the nMARQ TM and additional "point-by-point" ablation was required. Furthermore, phrenic nerve capture was also demonstrated in a quite large area around the RSPV antrum, so that, despite several attempts, a safe and complete PVI with the nMARQ TM catheter was not achieved and conventional ablation was needed to tailor the lesion line according to this specific anatomy.
An important limit of the nMARQ TM catheter pointed out by our results is that it was able to predict PVI only in 78% of PVs according to the Lasso catheter mapping. The evidence of a discordance between nMARQ TM and Lasso recording has been reported also by Rosso et al 13 .
Possible explanations may be the difference in inter-electrode spacing, the electrodes size and more proximal position in the PVs ostia of the nMARQ TM that may influence the endocardial electrograms characteristics. Further studies are necessary to evaluate the long term outcome of PVI obtained by the use of the nMARQ TM only in order to assess the impact of confirmation of PVI with Lasso mapping on the procedural outcome.
Regarding the X-ray exposure it should be considered that the nMARQ TM technology, combining ablation capability with the 3D navigation, allows to visualize the catheter and consequently to maneuver it without the need of fluoroscopy. In our series the mean total X-ray time was 1.8'±2", similar to that previously published 15 with conventional "point-by-point" RF ablation.
Fluoroscopy was used almost only for the transseptal puncture and the initial positioning of the catheters, while the combination with the CARTO 3 system allowed to perform mapping and RF delivery fluoroless. This result has an important clinical implication for the reduction of fluoroscopy exposure for the patient and medical staff.
Recently much attention has been raised regarding the occurrence of post-AF ablation SCI 8. With the use of multipolar non irrigated RF ablation catheters, PVAC, post-ablation SCI were detected in 38.9% of the cases 3 . Similar incidence ( 33%) has been reported by Deneke et al authors reported also 33% of esophageal lesions detected by endoscopy. 5 This complication was attributed to the use of high RF power in the posterior wall. In our series we declined the use of esophageal temperature monitoring because of a possible causal connection between multielectrode ablation and esophageal lesion by passive heating of the temperature probe. 17 However, for safety reason, we delivered a maximum of 18 watts RF energy in the posterior wall for no more than 40 seconds.
Finally, in our study, with the use of the nMARQ TM catheter a short-term success rate of 68% was achieved without AADs. However, our short-term follow up does not allow any firm conclusion and the outcome of the procedure needs to be assessed in further studies with longerfollow-up and with more accurate detection tools to exclude asymptomatic arrhythmias episodes.
Study limitations
This is a study with a limited sample size and a short follow up. Moreover, the follow-up was carried out only on a clinical basis, so that asymptomatic AF episodes may be missed.
Secondly, our acute and short term outcome cannot be attributed only to the use of the nMARQ TM technology because, in our study protocol, the Lasso catheter was used to confirm PVI. In addition, in one patient the use of the standard 3.5-mm tip open irrigated catheter was needed to complete PVI.
Another consideration regards the uncertainty of re Lasso recordings related to our study protocol since Lasso and nMARQ TM signals were not recorded simultaneously, but in temporal sequencing.
Moreover, another limitation is that the procedure was not performed with the widely used onwarfarin protocol, but with the bridge protocol between warfarin and LMWH with intraprocedural heparin infusion.
Finally, esophageal lesions were not assessed with endoscopy.
Conclusions
The limited size of our patient population does not allow any firm conclusion. However, our preliminary experience demonstrated the feasibility, the safety and the good acute procedural success of the PVI performed with the nMARQ TM catheter.
In addition an important result of our study is the complete absence of periprocedural SCI, in contrast with other experiences 5 using the same ablation catheter. This finding underlies the importance of following a specific and careful procedural workflow.
Our preliminary results need to be confirmed with long-term studies. Fluoro time during RF (sec) 2±9
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